Neoantigen Therapies Market Global Report 2026

The neoantigen therapies market size has grown exponentially in recent years. It will grow from $0.96 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 24.1%. The growth in the historic period can be attributed to increasing global cancer incidence rates, advancements in next-generation sequencing technologies, early adoption of personalized medicine approaches in oncology, rising clinical trial activity for immunotherapy treatments, and growing understanding of tumor mutational burden in cancer progression.

The neoantigen therapies market size is expected to see exponential growth in the next few years. It will grow to $2.83 billion in 2030 at a compound annual growth rate (CAGR) of 24.3%. The growth in the forecast period can be attributed to expansion of AI-driven bioinformatics platforms for antigen prediction, increasing regulatory approvals for personalized cancer vaccines, rising investments in precision oncology research pipelines, development of scalable off-the-shelf neoantigen platforms, and growing adoption of combination immunotherapy regimens in clinical oncology. Major trends in the forecast period include expansion of personalized neoantigen vaccine development using tumor-specific mutation profiling, increasing integration of AI-driven neoantigen prediction and epitope mapping for improved immunogenic accuracy, growth of mRNA-based and peptide-based individualized cancer immunotherapies targeting patient-specific tumor signatures, rising adoption of next-generation sequencing-guided precision oncology workflows for early tumor antigen identification, and advancement in combination immunotherapy approaches integrating neoantigen therapies with checkpoint inhibitors for enhanced tumor suppression.

The rising global incidence of cancer is expected to drive the expansion of the neoantigen therapies market in the coming years. Cancer incidence refers to the number of newly diagnosed cancer cases within a defined population over a specified time period, reflecting the increasing global burden of cancer. The growth in cancer incidence is primarily attributed to the aging population, as cancer risk increases with age due to the accumulation of genetic mutations and prolonged exposure to environmental risk factors. Neoantigen therapies contribute to cancer treatment by enabling highly personalized immunotherapy approaches that target tumor-specific mutations, thereby enhancing treatment precision and improving immune response effectiveness. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, it is projected that by 2050, more than 35 million new cancer cases will occur, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising global cancer incidence is driving the growth of the neoantigen therapies market.

Leading companies operating in the neoantigen therapies market are focusing on advancing personalized cancer immunotherapy solutions, such as individualized neoantigen vaccines, to improve tumor-specific immune responses, enhance treatment precision, and support long-term disease control. Individualized neoantigen vaccines refer to customized immunotherapies developed using patient-specific tumor mutation profiles to stimulate targeted immune attacks against cancer cells. For example, in April 2026, Transgene S.A., a France-based biotechnology company, announced the completion of randomization in its Phase II clinical trial evaluating TG4050, a personalized neoantigen therapeutic vaccine developed using its myvac platform. The therapy is designed to generate individualized immune responses against tumor-specific mutations in patients with head and neck cancer, supporting advancements in precision oncology and next-generation cancer immunotherapy development.

In January 2026, BioNTech SE, a Germany-based biotechnology company focused on mRNA-based immunotherapies and cancer treatment development, acquired CureVac N.V. for $5.46 billion. This acquisition strengthens BioNTech SE’s oncology and personalized cancer immunotherapy portfolio by expanding its capabilities in mRNA-based neoantigen therapies and individualized cancer vaccine development. CureVac N.V. is a Germany-based biotechnology company specializing in mRNA therapeutics, personalized cancer vaccines, and neoantigen-based immunotherapy platforms.

Major companies operating in the neoantigen therapies market are Moderna Inc., BioNTech SE, Agenus Inc., Immatics N.V., Elicio Therapeutics Inc., Nykode Therapeutics ASA, Creative Biolabs, Advaxis Inc., AIVITA Biomedical Inc., Medigene AG, Nouscom AG, Ultimovacs ASA, Geneos Therapeutics Inc., Treos Bio Limited, TVAX Biomedical Inc., Evaxion Biotech A/S, Circio Holding ASA, Transgene S.A., INTAVIS Peptide Services GmbH, Merck & Co., Bristol Myers Squibb, Roche/Genentech, AstraZeneca, GSK plc.

North America was the dominant region in the neoantigen therapies market in 2025. North America is expected to be the rapidly expanding region in the forecast period. The regions covered in neoantigen therapies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neoantigen therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neoantigen therapies market consists of revenues earned by entities by providing services such as genomic profiling, neoantigen identification, personalized vaccine development, immune cell engineering, clinical trial support, and precision oncology treatment solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neoantigen therapies market also includes sales of neoantigen peptide vaccines, neoantigen mrna therapeutics, dendritic cell-based immunotherapies, and neoantigen-targeted combination immunotherapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The neoantigen therapies market research report is one of a series of new reports that provides neoantigen therapies market statistics, including neoantigen therapies industry global market size, regional shares, competitors with a neoantigen therapies market share, detailed neoantigen therapies market segments, market trends and opportunities, and any further data you may need to thrive in the neoantigen therapies industry. This neoantigen therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.